Matt Outten, MBA, ALM, CPC
Chief Commercial Officer
Matt Outten, MBA, ALM, CPC is the Chief Commercial Officer for QED Therapeutics. Matt joins QED with over 17 years of pharmaceutical/biotech experience with a focus in oncology and product launches. Most recently, Matt held various leadership positions at Pharmacyclics including Vice President of Marketing and Market Access, Vice President Commercial Operations, Chief Commercial Officer, and also served as a company officer. During his tenure, he led the successful launch of Imbruvica for Chronic Lymphocytic Leukemia and celebrated approvals in five distinct disease states to help meet unmet needs for patients. Matt has also held roles of increasing responsibility across marketing, sales, and market access at pharmaceutical and biotech companies including Millennium Pharmaceuticals, Schering Plough, and GlaxoSmithKline. He has worked on over 12 products and multiple product launches with the last 10 years focused in oncology. Matt received his B.A. from Hamilton College, M.B.A from The University of Delaware, A.L.M from Harvard University, and is a certified professional coder.